Cybin Inc. (NYSE AMERICAN:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote. The post Cybin Shareholders Approve Acquisition of Small Pharma appeared...
Welcome to the fourth season of the Psychedelic Invest Podcast! It’s great to be back! On the season premiere episode, host Bruce Eckfeldt is joined...
MindBio Therapeutics Corp. have started selection of participants for its Phase 2 randomized double-blind and placebo controlled clinical trial in advanced...
–Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” – –...
The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual...
–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024...
Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD). The post atai Life Sciences Completes...
A Michigan lawmaker has relaunched efforts to legalize psychedelic fungi and plants with the caveat that all psychedelic-related activity does not involve...
The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of...